Nxera Pharma

Basic Information

Stock Code
4565
Industry
Pharmaceuticals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Tokyo
Establishment Year
June 1990
Listing Year
July 2004
Official Website
https://www.nxera.life/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
GNi Group, Heartseed, Synchro, JCR Pharma, AnGes, PeptiDream, SanaBio, Helios, Rena Science, QualiPs, Takara Bio, Net Pro, Japan Tissue Engineering

Overview

Nxera Pharma is a bio-venture in the pharmaceutical field founded in 1990, focusing on research, development, and sales of gene therapy drugs through drug discovery technology and global expansion.

Current Situation

Nxera Pharma recorded consolidated net sales of 17.7 billion yen, operating income of 3.8 billion yen, and net income of 1 billion yen in the fiscal year ended December 2021, achieving a turnaround to profitability. Its flagship products for COPD, Seebri and Ultibro, have succeeded in the global market, and it also sells the emergency contraceptive Norlevo. In recent years, it acquired Idorsia's APAC business for 65 billion yen, embarking on strengthening its sleep drug pipeline including daridorexant. In R&D, the acquisition of UK-based Heptares enhanced its GPCR-targeted therapy development capabilities. It has also licensed out drug candidates for central nervous system diseases, promoting product diversification. While engaging in sustainability and social contributions, it is pursuing aggressive expansion both domestically and internationally. Moving forward, it aims for significant sales growth toward 2030 through launches of growth products and strengthened R&D capabilities.

Trivia

Interesting Facts

  • One of the pioneering drug discovery bio-ventures in Japan.
  • Acquired international R&D capabilities through UK company acquisition.
  • First exclusive sales of emergency contraceptive Norlevo in Japan.
  • Long history dating back to Sosei parent company era.
  • Significantly grew stock price and sales after turning profitable.
  • Partnered with multiple major pharmaceutical companies in bio-pharma field.
  • Strengthened financial base through multiple capital increases.
  • Company name derived from words meaning innovation and freedom.
  • International company operating in both Japanese and European markets.
  • Norlevo tablets widely handled in medical institutions.
  • Gained APAC sales rights through Idorsia acquisition.
  • Advanced pipeline in sleep and cerebrovascular drugs.
  • Diverse product lineup addressing multiple diseases.
  • Strengthened patent rights through clinical successes.
  • Management team comprises industry experts with extensive pharma experience.

Hidden Connections

  • Founder is former president of Genentech Japan with strong industry connections.
  • Enhanced ties with European research institutions via Heptares acquisition.
  • Daridorexant inherited from Idorsia with APAC sales rights.
  • Norlevo Japan sales rights originated from contract with French HRA Pharma.
  • Schizophrenia candidate drug already licensed out to U.S. firm.
  • Constantly competes with AnGes in Japanese bio-venture market.
  • Actively engages in technology exchange with numerous bio-ventures.
  • Broad involvement with major pharma from joint development to sales partnerships.

Future Outlook

Growth Drivers

  • Increasing demand for COPD and CNS diseases due to aging population.
  • Product sales expansion strategy in Asia-Pacific markets.
  • Acceleration of GPCR-related drug discovery via Heptares acquisition.
  • New pipeline rollout from Idorsia acquisition.
  • New licensing revenue based on drug discovery and manufacturing strengths.
  • Revenue growth from new drug launches via clinical successes.
  • International partnerships for joint R&D.
  • Improved development efficiency through AI and digital technologies.
  • Enhanced corporate value via sustainability management.
  • Market risk diversification through entry into diverse disease areas.
  • Maintaining competitive edge through sustained technological innovation.
  • Stable growth funding via capital policies.

Strategic Goals

  • Strengthen global expansion to double sales.
  • Accelerate new drug creation in diverse disease areas.
  • Promote digitalization and efficiency in R&D.
  • Strengthen environmental load reduction and social contributions.
  • Expand global partnerships.
  • Focus on improving pharmaceutical quality and safety.
  • Enhance and upscale bio-pharmaceutical production capabilities.
  • Maximize talent utilization through diversity initiatives.
  • Expand products in schizophrenia and sleep drug areas.
  • Build systems for rapid response to medical field needs.

Business Segments

Drug Discovery Research Support

Overview
Provides research and development support and technology for drug discovery processes.
Competitiveness
Possesses advanced drug discovery technology and global network.
Customers
  • Pharmaceutical companies
  • Biotechnology firms
  • Universities and research institutions
  • Public research institutions
Products
  • GPCR target candidate compounds
  • Gene therapy technologies
  • Drug discovery candidate compounds
  • Contract development research (CRO)

Technology Licensing and Partnerships

Overview
Promotes licensing of pharmaceutical candidates and joint development. Provides technology.
Competitiveness
Extensive partnership network and track record.
Customers
  • Domestic and international pharmaceutical companies
  • Bio-ventures
Products
  • Licensing out of pharmaceutical candidate compounds
  • Technology partnership agreements

API and Pharmaceutical Manufacturing Contract

Overview
Provides quality-controlled pharmaceutical APIs and formulation manufacturing services.
Competitiveness
High-quality manufacturing management system.
Customers
  • Pharmaceutical manufacturers
  • Generic manufacturers
Products
  • API supply
  • Formulation contract manufacturing

Sales Agency and Marketing Support

Overview
Supports pharmaceutical sales agency and marketing mainly in the Japanese market.
Competitiveness
Domestic sales network and regulatory compliance knowledge.
Customers
  • Small and medium pharmaceutical companies
  • Healthcare-related companies
Products
  • Sales agency services
  • Marketing support

Competitive Advantage

Strengths

  • Global drug discovery R&D framework
  • Advanced GPCR drug discovery technology
  • Numerous international patents held
  • Strong acquisition and licensing strategy
  • Diverse therapeutic area pipeline
  • Achieved profitability with solid financial base
  • Extensive domestic and international sales network
  • High R&D investment and technological continuity
  • Established new drug development process
  • Track record of partnerships with multinational pharma
  • Mature gene therapy technology
  • Specialized pharmaceutical manufacturing capabilities
  • Strong management team and experienced personnel
  • Aggressive overseas business expansion strategy
  • Entry into schizophrenia and other neuropsychiatric areas

Competitive Advantages

  • Secured cutting-edge GPCR research technology through acquisition of UK Heptares
  • Holds multiple approved pharmaceuticals including emergency contraceptive Norlevo
  • Future growth expected from numerous clinical trial pipelines
  • Technology protection and market entry barriers via international patents
  • Strong sales foundation in Japan and Asia-Pacific
  • Risk diversification through treatments for diverse diseases
  • Aggressive M&A to expand R&D and product portfolio
  • World-class researcher team and global operations
  • Stable funding through IPO and investor support
  • Pipeline specialized in key areas to meet medical needs
  • Research acceleration via strategic partnerships
  • Large-scale acquisitions and global expansion leveraging capital
  • Ownership of high-value pharmaceutical manufacturing technology
  • Developing innovative therapies jointly with multinationals
  • Top-tier market valuation among Japanese bio-ventures

Threats

  • Risk of development delays from clinical trial failures
  • Intense competition among rivals in development
  • Potential strengthening of drug price regulations
  • Competitor generic entry upon patent expiration
  • Delays in regulatory approvals
  • Revenue impact from exchange rate fluctuations
  • Rising R&D costs and funding challenges
  • Market demand fluctuations and healthcare policy changes
  • Intensifying competition with generics
  • Supply chain impacts from international instability
  • Difficulty keeping pace with accelerating technological innovation
  • Market share erosion by new entrants

Innovations

2024: Company name change and business reorganization completed

Overview
Changed name from Sosei Group to Nxera Pharma and reorganized subsidiaries.
Impact
Brand refresh and business integration synergies

2023: Idorsia APAC business acquisition

Overview
Acquired Swiss pharma giant Idorsia's Asia business for approx. 65 billion yen to expand pipeline.
Impact
Expansion into new areas like sleep drugs and strengthened revenue base

2021: Schizophrenia drug NBI-1117568 licensed out

Overview
Licensed novel muscarinic receptor agonist to U.S.-based Neurocrine.
Impact
Entry into CNS area and increased future revenue potential

2020: Cancer immunotherapy development partnership

Overview
Entered joint research agreement with AstraZeneca on cancer immunotherapy.
Impact
Accelerated new therapy development and enhanced technology

Sustainability

  • Promoting green chemistry in pharmaceutical operations
  • Introducing low-environmental-impact manufacturing processes
  • CSR activities emphasizing regional healthcare support
  • Establishment of sustainable procurement policies
  • Efforts to increase female executive ratio
  • Employee health management programs
  • Ethics codes and compliance training
  • Efforts to reduce CO2 emissions in business activities
  • Maintaining patient-centered drug development
  • Diversity and inclusion enhancement measures